Medicine
Paul Scherrer Institute and Apollo Health Ventures Launch Focal Biosciences
Newly established Focal Biosciences will focus on bringing together leading experts and scientific discoveries to harness cellular reprogramming in the fight against common age-related diseases.
Making tumour diagnosis kinder to kidneys
Improved method thanks to a molecular trick
Swissmedic grants operating licence for new radiopharmaceutical production facility
From research to production – the new pharmaceutical lab at PSI supplies neighbouring hospitals with novel cancer drugs.
Nominated: High-precision X-rays of breast tissue
Employing high-resolution X-rays to diagnose breast cancer – PSI researchers nominated for the European Inventor Award.
Asthma: diagnosis in a single breath
PSI is involved in the development of a breath test that can be used to diagnose asthma. Imad El Haddad explains why such a test could be extremely useful – especially for children.
New, better coronavirus rapid test
The test identifies different virus variants and improves disease prognosis.
The power of protons
This gallery presents five people who have been treated at the PSI's Center for Proton Therapy.
KSB and PSI forge a common research path
Kantonsspital Baden and the Paul Scherrer Institute PSI have signed a cooperation agreement.
Effective combination cancer treatment
Combining two chemotherapeutic drugs inhibits tumour growth.
New catalysts for pharmaceutical companies
In partnership with Roche, PSI scientists are developing new, potentially more efficient catalysts for manufacturing active substances for drug therapies.
Proton therapy: a success story that started 25 years ago
25 November 1996: a world first for PSI’s Center for Proton Therapy in treating a cancer patient using the spot-scanning technique.
A first for Switzerland: proton therapy to treat lung cancer
On 9 November 2021 a lung cancer patient was given proton therapy at the Paul Scherrer Institute PSI for the first time in Switzerland.
New active agent against parasites
PSI researchers identify potential active agent against several unicellular parasites – including the pathogens that cause malaria and toxoplasmosis.
Tracking down unreported Coronavirus cases
The University Hospital of Zurich uses proteins made at PSI for Europe’s first large-scale serology study on coronavirus prevalence in Switzerland.
PSI: advancing in the fight against Covid-19
Crystal structure analysis, computer models, cell cultures – to pursue research on Sars-CoV-2, PSI is exploring many avenues. An overview.
How immune cells are activated
A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases.
How remdesivir works against the coronavirus
Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.
"Ultimately, we aim to understand how diseases start in single cells"
Imaging and sequencing techniques combined with machine learning offer researchers countless opportunities to look inside cells with greater precision than ever before. G.V. Shivashankar, lab head at PSI, describes how such information can be used to find answers to pressing questions.
Wait and see, and grow crystals
At PSI, researchers decipher the structure of the proteins in bacteria and viruses. This knowledge can aid, for example, in the development of drugs against infectious diseases. But before the investigation can begin, an extremely tricky problem has to be solved: the crystallisation of the molecules.
A protein's unexpected "doming"
Researchers have coaxed a secret out of the vital protein cytochrome c that it kept well-hidden up to now. Measurements at the X-ray free-electron laser SwissFEL reveal structural changes that science had previously ruled out for this kind of biomolecule.
